Modular Medical, Inc.
Modular Medical, Inc. is a U.S.-based pre-revenue medical device company developing insulin pump systems for people with diabetes. Its core effort is to commercialize a low-cost, easier-to-use patch pump platform, starting with MODD1 and then a next-generation tubeless version called Pivot.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaWearable insulin delivery devices designed for people requiring multiple daily insulin doses.
Tubeless and simplified pump designs intended to improve usability and manufacturability.
FDA clearance, manufacturing transfer, and launch preparation needed to bring products to market.
Asiakkaat
The company targets insulin-dependent diabetes patients, especially people with type 1 diabetes and a growing type 2 population using multiple daily injections. It also sells through the healthcare channel, relying on diabetes educator practices, primary care physicians, distributors, and payors to support adoption and reimbursement.
Buy or are prescribed insulin pumps for continuous, wearable insulin delivery and better daily management.
Targeted as a larger, underpenetrated group that may adopt pumps if the device is simpler and lower cost.
Prescribe and train patients on pump use, making them a key channel for adoption and support.
Help reach daily insulin users who are not managed by specialist pump centers.
Strategia
The company’s strategy is to win adoption by simplifying insulin pump use, lowering training burden, and reducing cost versus existing devices. It is also shifting toward a more manufacturable next-generation product, Pivot, while building a channel model that combines distributors with a focused direct sales effort to diabetes educator practices.
The company needs first product revenue and real-world adoption to validate the platform and channel strategy.
Pivot is intended to replace MODD1 with a more usable and manufacturable product.
The company is trying to expand beyond specialist pump users into a broader diabetes market.
Maantiede
Modular Medical is headquartered and operates in San Diego, California, and all employees are located in the United States. The company currently focuses on the U.S. market, where it has FDA clearance for MODD1 and is preparing commercial launch, while also planning future foreign regulatory approvals.
Riskit
The company is pre-revenue and depends on external financing, so execution risk and dilution risk are central. It also faces regulatory, manufacturing, reimbursement, and competitive risks typical of medical device commercialization, with larger rivals already established in insulin pumps.
- Going concern and financing dependenceVaikutus: KriittinenTodennäköisyys: Korkea
The company states substantial doubt about its ability to continue without additional capital.
Kohdistuu: Equity and debt financing needs to fund R&D and commercialization
- Regulatory approval and FDA complianceVaikutus: KorkeaTodennäköisyys: Korkea
Commercial launch depends on 510(k) clearance and ongoing quality-system compliance.
Kohdistuu - Manufacturing and supply chain executionVaikutus: KorkeaTodennäköisyys: Korkea
The company must transfer production and maintain compliant contract manufacturing.
Kohdistuu - Competitive pressure from established pump makersVaikutus: KorkeaTodennäköisyys: Korkea
Medtronic, Tandem Diabetes Care, and Insulet have larger resources and installed bases.
Kohdistuu - Reimbursement and adoption frictionVaikutus: KeskitasoTodennäköisyys: Korkea
Insurance coverage and training economics affect whether clinicians prescribe and support the device.
Kohdistuu: Commercial uptake and channel efficiency
Kirjanpito
Harkinnanvaraiset erätR&D is the main operating cost and is expensed as incurred, so it directly shapes reported losses.
Vaikutus: High and rising R&D can obscure underlying commercialization progress
As a small public company, equity awards may be an important part of compensation and dilution.
Vaikutus: Affects operating expense and shareholder dilution
Management must estimate accruals, taxes, and other liabilities in a development-stage business.
Vaikutus: Can move quarterly results materially
The company has disclosed substantial doubt about continuing without new financing.
Vaikutus: Important for liquidity analysis and balance-sheet interpretation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
ICU Medical, Inc
ICUI · Surgical & Medical Instruments & Apparatus
ICU Medical develops, manufactures, and sells medical devices and software used in infusion therapy, vascular access, and critical care settings.
Päivitetty: 24.9.2026